Drug intelligence / Profile preview

CS1012

Development stage: Preclinical
Lead developer: CStone Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CS1012 is a monoclonal antibody targeting growth differentiation factor 15 (GDF-15), currently in preclinical development by CStone Pharmaceuticals for the treatment of solid tumors. GDF-15 is a stress-response cytokine that is frequently upregulated in various cancers and is associated with tumor progression, immunosuppression, and cancer cachexia. By targeting and neutralizing GDF-15, CS1012 aims to reverse GDF-15-mediated immunosuppression in the tumor microenvironment and potentially alleviate cancer-associated cachexia, thereby offering a therapeutic benefit for patients with advanced solid tumors.

Targets

GDF15 (Growth differentiation factor 15)

Beyond the preview

Go deeper on CS1012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS1012.

Explore the full profile